Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Australian Care Magic Hirudin Peptid
Brand Name
Australian Care Magic Hirudin Peptid
Generic Name
Australian Care Magic Hirudin Peptid
Active Ingredient
HirudinCategory
Copper-containing Intrauterine Device [EPC]
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 600 mg/1200mg | PELLET | ORAL | 85119-001 |
Detailed information about Australian Care Magic Hirudin Peptid
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Australian Care Magic Hirudin Peptid, you must consult a qualified healthcare professional.
Hirudin is a potent direct thrombin inhibitor originally derived from medicinal leeches, primarily used as an anticoagulant and for diagnostic allergenic testing in specific clinical settings.
Dosage for Hirudin derivatives must be strictly individualized based on the patient's weight, clinical indication, and renal function.
For patients undergoing elective hip replacement, the standard dose of Desirudin is 15 mg administered subcutaneously every 12 hours. The first dose is typically given 5 to 15 minutes before surgery, though some protocols initiate it post-operatively. Treatment usually continues for 9 to 12 days or until the patient is fully mobile.
When using Lepirudin (where available), the dosage is complex and requires a bolus followed by a continuous infusion. A typical bolus is 0.4 mg/kg (up to 110 kg) followed by an infusion of 0.15 mg/kg/hour. The rate is adjusted based on the Activated Partial Thromboplastin Time (aPTT) to maintain a ratio of 1.5 to 2.5 times the laboratory's median normal value.
Hirudin and its recombinant analogues are not currently FDA-approved for use in pediatric patients. The safety and effectiveness in children have not been established in large-scale clinical trials. If used off-label in life-threatening HIT cases within a pediatric intensive care unit, dosing is calculated strictly by weight and monitored with extreme frequency by specialized hematologists.
Since Hirudin is primarily cleared by the kidneys, dose adjustments are mandatory for patients with impaired renal function to avoid toxic accumulation and life-threatening bleeding.
No specific dose adjustments are generally required for hepatic (liver) impairment, as the drug is not metabolized by the liver. However, patients with severe liver disease may have baseline coagulation deficits, increasing the risk of bleeding.
Geriatric patients often have age-related declines in renal function. Healthcare providers usually calculate the Creatinine Clearance (CrCl) before initiating Hirudin to ensure the starting dose is appropriate. The risk of bleeding is significantly higher in patients over the age of 75.
Hirudin is administered via injection. If you are receiving this in a hospital, a nurse or doctor will perform the injection. If you are prescribed Desirudin for home use after hip surgery:
If you are using Hirudin at home and miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up, as this significantly increases the risk of internal bleeding.
There is no specific neutralizing 'antidote' for Hirudin. In the event of an overdose, the primary symptom is uncontrollable bleeding (hemorrhage).
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
The most common side effects associated with Hirudin therapy involve the drug's intended pharmacological action: thinning the blood.
> Warning: Stop taking Hirudin and call your doctor immediately or seek emergency care if you experience any of the following:
Hirudin is typically used for short-term acute care (days to weeks). Long-term effects are not well-documented in humans. However, the primary concern with repeated use over time is the increasing likelihood of developing antibodies, which can lead to severe allergic reactions upon re-exposure or unpredictable drug levels in the blood.
Spinal/Epidural Hematoma Warning:
When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients anticoagulated with Hirudin (specifically Desirudin) are at risk of developing an epidural or spinal hematoma. This can result in long-term or permanent paralysis. The risk is increased by the use of indwelling epidural catheters, concomitant use of NSAIDs or platelet inhibitors, and traumatic or repeated punctures. Patients must be monitored frequently for neurological impairment.
Report any unusual symptoms to your healthcare provider.
Hirudin is a high-alert medication. Because it binds irreversibly to thrombin and has no specific reversal agent, any dosing error or patient-specific risk factor can lead to catastrophic bleeding. It must only be used in clinical settings where coagulation parameters (like aPTT) can be monitored closely.
Hirudin derivatives like Desirudin carry a Black Box Warning regarding the risk of spinal or epidural hematomas. Patients undergoing spinal procedures (like an epidural for pain relief during surgery) while on Hirudin may experience bleeding into the spinal column. This pressure can cause permanent paralysis. Doctors will typically wait a specific number of hours after the last dose before placing or removing a spinal catheter.
If you are on Hirudin, your healthcare team will perform the following tests:
Hirudin itself does not usually cause drowsiness or impair cognitive function. However, the conditions it treats (like recovery from major surgery) and the risk of sudden dizziness from blood loss mean you should not drive or operate heavy machinery until your doctor confirms it is safe.
Alcohol should be strictly avoided while taking Hirudin. Alcohol can thin the blood further and increase the risk of stomach bleeding. It also increases the risk of falls, which can be fatal for someone on a potent anticoagulant due to the risk of brain bleeds.
Do not stop taking Hirudin suddenly unless directed by your doctor. Stopping an anticoagulant prematurely can lead to the sudden formation of blood clots, which can travel to the lungs (pulmonary embolism) or brain (stroke). If you are transitioning to an oral anticoagulant like Warfarin, your doctor will 'overlap' the medications for several days.
> Important: Discuss all your medical conditions with your healthcare provider before starting Hirudin.
Many herbal supplements have natural 'blood-thinning' properties and should be discontinued at least 2 weeks before Hirudin therapy if possible:
Hirudin will affect almost all coagulation-based lab tests. It will prolong the Prothrombin Time (PT), International Normalized Ratio (INR), and Thrombin Time (TT). If you are having a blood test for a clotting disorder (like Protein C or S deficiency), ensure the lab knows you are on Hirudin, as it can cause false-positive or false-negative results.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Hirudin must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by a specialist:
Patients with known allergies to yeast (specifically Saccharomyces cerevisiae) should be treated with caution, as some recombinant Hirudin products are manufactured using yeast cells and may contain trace amounts of yeast proteins.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Hirudin.
Hirudin is generally classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown some developmental toxicity at doses that were also toxic to the mother.
It is unknown whether Hirudin or its derivatives are excreted in human milk. Because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants (such as internal bleeding), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
As previously stated, Hirudin is not approved for pediatric use. Children have different coagulation systems than adults, and the risk of bleeding may be higher. If used, it requires an expert pediatric hematologist and constant monitoring in an ICU setting.
Clinical studies of Desirudin included a significant number of patients over 65. No overall differences in safety or effectiveness were observed between these patients and younger patients. However, the elderly are more likely to have decreased renal function. Because Hirudin is cleared by the kidneys, the risk of toxic reactions is greater in patients with impaired renal function. Doctors will typically perform a 'Cockcroft-Gault' calculation to estimate kidney function before dosing an elderly patient.
Renal impairment is the most significant factor in Hirudin safety.
While the drug is not cleared by the liver, patients with hepatic impairment (Child-Pugh Class B or C) often have a reduced ability to produce clotting factors. This 'auto-anticoagulation' makes them hypersensitive to Hirudin. Dose monitoring with aPTT must be even more frequent in this population.
> Important: Special populations require individualized medical assessment.
Hirudin is a highly specific, bivalent direct thrombin inhibitor. Its structure allows it to bind with extremely high affinity to two sites on the thrombin molecule:
By blocking both sites, Hirudin prevents thrombin from converting fibrinogen to fibrin, prevents thrombin-induced platelet activation, and prevents the activation of Factors V, VIII, and XIII. Unlike heparin, Hirudin can inhibit both free-floating thrombin and thrombin that is already bound to a clot.
The anticoagulant effect of Hirudin is dose-dependent. The onset of action is rapid (within minutes of IV administration and ~1 hour for SC). The duration of effect is tied to its half-life; once the drug is cleared from the blood, thrombin activity returns to normal relatively quickly. There is no 'ceiling effect' for Hirudin, meaning higher doses continue to increase the anticoagulant effect until the blood is unable to clot at all.
| Parameter | Value |
|---|---|
| Bioavailability | 85% - 90% (Subcutaneous) |
| Protein Binding | < 10% (Minimal) |
| Half-life | 1.5 - 3 hours (Normal Renal Function) |
| Tmax | 1 - 3 hours |
| Metabolism | Negligible (Proteolysis) |
| Excretion | Renal 90% (unchanged drug) |
Hirudin belongs to the Direct Thrombin Inhibitor (DTI) class. It is further categorized as a Bivalent DTI, distinguishing it from univalent DTIs like Argatroban. It is also classified for regulatory purposes as an Allergenic Extract when used in diagnostic skin testing.
Common questions about Australian Care Magic Hirudin Peptid
Hirudin and its recombinant forms are primarily used as potent anticoagulants to prevent and treat blood clots. Its most critical use is in patients with Heparin-Induced Thrombocytopenia (HIT), a condition where patients cannot use standard heparin due to a dangerous immune reaction. It is also used to prevent deep vein thrombosis (DVT) in patients undergoing major surgeries like hip replacements. Additionally, it serves as a diagnostic tool in allergy testing for patients who may be sensitive to leech-derived proteins. Because it works directly on thrombin, it is effective in specialized cases where other blood thinners fail.
The most frequent side effects of Hirudin are related to its blood-thinning properties, including easy bruising, minor bleeding from the gums, and redness or swelling at the injection site. Some patients may also experience anemia, nausea, or a mild fever following surgery. Because it is a protein-based medication, minor skin rashes or hives can occur in sensitive individuals. More serious side effects, though less common, include major internal bleeding or severe allergic reactions. Always report any unusual bruising or persistent bleeding to your healthcare provider immediately.
No, you should strictly avoid alcohol while being treated with Hirudin. Alcohol can enhance the anticoagulant effect of the medication, significantly increasing your risk of dangerous internal bleeding, especially in the stomach or brain. Furthermore, alcohol can impair your coordination, increasing the risk of falls; for a patient on Hirudin, even a minor fall can result in a life-threatening hemorrhage. Alcohol also interferes with the liver's ability to produce other clotting factors, making the drug's effects unpredictable. Always consult your doctor before consuming any alcoholic beverages during treatment.
Hirudin is generally not recommended during pregnancy unless the benefits clearly outweigh the risks, as it is classified as Pregnancy Category C. There is limited data on its effects in human pregnancy, but animal studies have suggested potential risks to the developing fetus at high doses. The primary concern is the risk of maternal hemorrhage, particularly during labor and delivery. If you are pregnant or planning to become pregnant, your doctor will likely explore other anticoagulation options that have more established safety profiles. It should only be used in life-threatening situations like severe HIT.
Hirudin works very quickly once it enters the bloodstream. When administered through an intravenous (IV) infusion, the anticoagulant effect is almost immediate. If given as a subcutaneous injection (under the skin), it typically reaches its peak effectiveness within 1 to 3 hours. Because it binds directly to thrombin, it begins neutralizing the clotting process as soon as the molecules come into contact with the enzyme. Your doctor will monitor your blood's clotting time (using the aPTT test) to ensure the drug is working at the desired level within a few hours of the first dose.
You should never stop taking Hirudin suddenly without explicit instructions from your healthcare provider. Hirudin is usually prescribed for a specific duration to prevent life-threatening blood clots after surgery or during an acute illness. Stopping the medication prematurely can cause a 'rebound' effect where your blood begins to clot too quickly, potentially leading to a stroke, heart attack, or pulmonary embolism. If your treatment needs to end, your doctor will typically transition you to an oral blood thinner or monitor you closely to ensure your safety. Always finish the full course as prescribed.
If you miss a dose of Hirudin, take it as soon as you remember, provided it is not too close to your next scheduled dose. If it is nearly time for your next injection, skip the missed dose and continue with your regular schedule. You must never take two doses at once to make up for a missed one, as this can lead to dangerously high levels of the drug in your system and cause severe bleeding. If you are unsure what to do, contact your doctor or pharmacist immediately for guidance. Consistency is key to maintaining safe anticoagulation levels.
There is no clinical evidence to suggest that Hirudin causes weight gain. It is a protein-based medication used for short-term anticoagulation and does not affect the metabolic processes or appetite centers that typically lead to weight changes. If you notice sudden weight gain or swelling (edema) while taking Hirudin, it is more likely related to other factors, such as fluid retention after surgery or other medications you may be taking. Always discuss any unexpected physical changes with your medical team to determine the underlying cause.
Hirudin has several significant drug interactions, particularly with other medications that affect blood clotting. Taking it with aspirin, NSAIDs (like ibuprofen), or other anticoagulants (like warfarin) greatly increases the risk of bleeding. Certain antidepressants (SSRIs) and many herbal supplements (like ginkgo or garlic) can also interact with Hirudin. Because of these risks, it is vital that you provide your doctor with a complete list of all prescription drugs, over-the-counter medicines, and supplements you are taking. Your doctor will carefully manage these combinations to prevent complications.
Currently, Hirudin is available primarily in its recombinant forms, such as Desirudin. While some brand-name versions like Refludan (Lepirudin) have been discontinued in certain markets, generic versions are not as widely available as more common drugs like lisinopril or metformin. This is because Hirudin is a complex biological product (a protein) rather than a simple chemical, making the production of 'biosimilars' or generics more difficult and expensive. Most patients receive the brand-name version available in their hospital or region, and cost-assistance programs may be available through the manufacturer.